✦ LIBER ✦

Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland

✍ Scribed by David S. Alberts; Michael R. Manning; Stanley W. Coulthard; Charles F. Koopmann Jr.; Terence S. Herman

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 322 KB
Volume: 47
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19810215)47:4<645::aid-cncr2820470404>3.0.co;2-a

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cyclophosphamide, doxorubicin, and cispl

Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin

✍ Arnon I. Dreyfuss; John R. Clark; Barbara G. Fallon; Marshall R. Posner; Charles 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 408 KB 👁 2 views

Thirteen patients with carcinomas of major and minor salivary gland origin (nine adenoid cystic carcinomas and four adenocarcinomas) were treated with cyclophosphamide (500 mg/m2), doxorubicin (50 mg/m2), and cisplatin (50 mg/m2) (CAP) by intravenous injections on the first day of a 28-day regimen.

A study of cyclophosphamide, adriamycin,

A study of cyclophosphamide, adriamycin, cis-platinum, and methotrexate in advanced transitional cell carcinoma of the urinary tract

✍ Dennis L. Citrin; Tom F. Hogan; Tom E. Davis 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Twenty patients with locally advanced and/or metastatic transitional cell cancer of the urinary tract were treated with cyclophosphamide 500 mg/m2, Adriamycin (doxorubicin) 40 mg/m2 and cis-platinum (CDDP) 40 mg/m2 given every three weeks for 2 cycles, alternating with methotrexate 40 mg/m2 weekly f

Chemotherapy for metastatic transitional

Chemotherapy for metastatic transitional carcinoma of the urinary tract: A prospective trial of methotrexate, adriamycin, and cyclophosphamide (MAC) with cis-platinum for failure

✍ I. F. Tannock; M. Gospodarowicz; W. K. Evans 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB 👁 1 views

Chemotherapy for advanced head and neck

Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen

✍ Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB 👁 2 views

Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m2, day 1; cyclophosphamide, 400 mg/m2, day 3; and cis-diamminedichloroplatinum, 20 mg/m2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0112 squamous cell carcinomas; 112 ad

Paclitaxel, 5-fluorouracil, and cisplati

Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma

✍ Yeul H. Kim; Sang W. Shin; Byung S. Kim; Jin H. Kim; Jong G. Kim; Young J. Mok; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Background: Although the clinical efficacy of paclitaxel in the treatment of gastric carcinoma has not been clearly defined, recent reports have suggested a possible role in the treatment of upper gastrointestinal carcinomas in vitro and in vivo. in this study, the authors evaluated the efficacy

Results of initial doxorubicin, 5-fluoro

Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast

✍ F. Maloisel; P. Dufour; J. P. Bergerat; R. Herbrecht; B. Duclos; A. Boilletot; C 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 400 KB 👁 2 views